BioCentury

7:00 AM GMT, Jun 15, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Arguing for a Third Way

With two oral multi-kinase inhibitors ahead of it in the market, GlaxoSmithKline plc hopes to position its pazopanib as the agent of choice for front-line treatment of renal cell carcinoma based on a better safety and tolerability profile.

Sutent sunitinib, a small molecule inhibitor of multiple tyrosine kinase receptors from Pfizer Inc., has been widely adopted as the front-line therapy of choice in the U.S. and Europe since its approval in early 2006, according to Debasish Roychowdhury, SVP and head of medicines development in GSK's oncology division. Nexavar sorafenib, a multi-kinase inhibitor from

Read the full 920 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.